Moxazocine
Moxazocine is a synthetic opioid analgesic that was developed in the 1970s. It is a member of the benzomorphan class of opioids and is known for its potent analgesic properties. Moxazocine has been studied for its potential use in pain management, but it has not been widely adopted in clinical practice.
Pharmacology[edit | edit source]
Moxazocine acts primarily as an agonist at the kappa-opioid receptor (KOR) and has partial agonist activity at the mu-opioid receptor (MOR). The activation of KOR is associated with analgesia, dysphoria, and psychotomimetic effects, while MOR activation typically results in euphoria, analgesia, and respiratory depression. The unique receptor profile of moxazocine contributes to its distinct pharmacological effects compared to other opioids.
Clinical Use[edit | edit source]
Despite its potent analgesic properties, moxazocine has not been widely used in clinical settings. This is partly due to its side effect profile, which includes significant dysphoria and psychotomimetic effects that limit its acceptability among patients. Additionally, the development of other opioid analgesics with more favorable side effect profiles has overshadowed the potential use of moxazocine.
Side Effects[edit | edit source]
The side effects of moxazocine are similar to those of other opioids and include:
Legal Status[edit | edit source]
Moxazocine is not widely available and is not listed as a controlled substance in many countries. However, its use is limited to research settings, and it has not been approved for medical use by major regulatory agencies such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA).
Research[edit | edit source]
Research on moxazocine has primarily focused on its pharmacological properties and potential therapeutic applications. Studies have explored its efficacy in pain management and its side effect profile compared to other opioids. However, due to its limited clinical use, research on moxazocine has been relatively sparse.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
